- Ko TYL, Miras AD, Pournaras DJ, Le Roux CW. Beyond BMI: Practical Guide for Clinicians to Integrate the Lancet Commission’s Obesity Framework and King’s Obesity Staging System Clin Obes
-
Looney E, Duffy M, Dutch D, Brown V, Browne J, Devane D, Harrington JM, Hayes C, Johnson BJ, Kearney PM, Kirkham JJ, Leahy-Warren P, Murphy AW, Redsell S, Seidler AL, Skouteris H, Dahly D, Matvienko-Sikar K.
Factors influencing use and choice of Core Outcome Sets and Outcome Measurement Instruments in trials of interventions to prevent childhood obesity: a mixed-methods survey J Clin Epidemiol
- Chong MC, Ko TYL, le Roux PL, le Roux CW. Changes in Eating Behaviour During Treatment With Obesity Medications Clin Obes
- Ozairi EA, Taghadom E, Irshad M, Yousef AA, AlKandari J, Al-Najim W, Alabdulkader S, Miras AD, le Roux CW. Combining glucagon-like peptide 1 analogues with sodium-glucose cotransporter 2 inhibitors to treat patients with type 1 diabetes, BMI > 25 kg/m(2), and chronic kidney disease – A randomised, controlled pilot study Diabetes Res Clin Pract
-
Davey MG, Donlon NE, Clerkin M, Bolger JC, Robb WB.
Minimally Invasive Hypoabsorptive Bariatric Surgery – A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials Obes Surg
-
Dubois L, Bédard B, Goulet D, Prud'homme D, Tremblay RE, Boivin M.
Food patterns and body weight in young adulthood and associations with food consumption throughout childhood: findings from a birth-cohort study Br J Nutr
- Keely SJ, Barrett KE. The role of the gut in obesity – new insights into the physiology of therapeutic approaches J Physiol
-
Brennan DJ, Lynch L.
Will GLP-1 Agonists Weaken the Links between Obesity and Cancer? Cancer Discov
-
le Roux CW, Wharton S, Bozkurt B, Platz E, Bleckert G, Ajaz Hussain S, Brueckmann M, Startseva E, Kloer IM, Kaplan LM.
Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1) Diabetes Obes Metab
-
Chumakova M, Finucane FM, Chen YJ, Juo YY.
Impact of the 2025 Lancet Diagnostic Criteria on Obesity Treatment in the United States Clin Obes